Search

To investigate the correlation between the levels of endogenous Apela, NT-proBNP and IL-6 in the serum of patients with heart failure and ventricular remodeling and cardiac reserve function. From May 2018 to May 2021, 120 patients with heart failure after AMI were enrolled in the study. Participants were divided into two groups: ventricular remodeling group (n=51) and non-ventricular remodeling group (n=69). In addition, 47 healthy subjects who received physical examination during the same period were selected as controls. In addition to left ventricular wall thickness (LVWT) and left ventricular mass index (LVMI), serum endogenous Apela, NT-proBNP and IL-6 expression levels were also measured. Analyze the correlation between serum endogenous Apela, NT-proBNP and IL-6 with LVWT and LVMI, and evaluate their value in predicting ventricular remodeling. Use 6MWT value, D/S value and Δ WMSI to assess cardiac reserve function. The left ventricular wall thickness (LVWT) and LVMI were different among the three groups (P<0.05); Compared with the control group, serum endogenous Apela levels were lower in the ventricular remodeling group and non-ventricular remodeling group, while IL-6 and NT-probNP levels were higher. The levels of Apela in the ventricular remodeling group were lower than those in the non-ventricular remodeling group, while the levels of IL-6 and NT-probNP were higher than those in the non-ventricular remodeling group. There were differences in serum endogenous Apela, IL-6 and NT-probNP levels among the three groups (P<0.05); In patients with heart failure after AMI, serum endogenous Apela was negatively correlated with LVWT and LVMI (r=-0.485, -0.428; P=0.001, 0.007). In addition, serum IL-6 and NT-probNP were significantly positively correlated with LVWT and LVMI (r=0.512, 0.426; P=0.000, 0.000) (r=0.592, 0.530; P=0.000, 0.000); Logistic regression analysis showed that the lower the serum Apela level, the higher the serum IL-6 and NT-probNP levels, the greater the possibility of ventricular remodeling. Therefore, serum endogenous Apela, IL-6, NT-probNP and Killip grading are risk factors for ventricular remodeling. Early combined detection of serum endogenous Apela, IL-6 and NT-probNP levels can improve the accuracy of predicting ventricular remodeling and contribute to the early prevention and treatment of heart failure after AMI. [ABSTRACT FROM AUTHOR]

Objective: To investigate the effects of creatine phosphate sodium on cardiomyocyte apoptosis and the expression of interleukin (IL)-6 and tumor necrosis factor (TNF)-α in high glucose cultured. Methods: The cardiomyocytes of SD rats were divided into three groups-normal group, heart failure group, and sodium creatine phosphate group. The heart failure group was cultured with serum-containing high glucose DMEM medium (33 mmol/L glucose); creatine phosphate sodium group was cultured with serum-containing high glucose DMEM medium (33 mmol/L glucose) and 100 α mol/L creatine phosphate sodium; the normal group was cultured with 10 % serum-containing DMEM medium (5.5 mmol/L glucose). MTT method was used to detect cell proliferation index; flow cytometry was used to detect cell apoptosis index; enzyme-linked immunosorbent assay was used to detect the content of IL-6 and TNF-α in the supernatant; Western blot method was used to detect Caspase-3, B-cell lymphoma-2 (Bcl-2) protein level. Results: 24 h and 48 h after treatment, the proliferation indexes of myocardial cells in the sodium phosphate creatine group were higher than those in the heart failure group (P<0.05), and the apoptosis index, Caspase-3 and Bcl-2 protein, IL-6, TNF-α The relative expression of α content were lower than those in the heart failure group (P<0.05), and there was no significant difference compared with the normal group (P>0.05). Conclusions: The application of creatine phosphate sodium in rat cardiomyocyte heart failure model can reduce the expression of Caspase-3 and Bcl-2 protein in cardiomyocytes, inhibit cell apoptosis and increase cell proliferation index. [ABSTRACT FROM AUTHOR]

BACKGROUND: Osteoarthritis (OA) is a kind of chronic bone and joint disease which seriously endangers human health. Cell therapy for OA has aroused widespread concern and gotten rapid development in recent years. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) have the advantages of easy amplification and differentiation, anti-inflammation and recruiting function such as MSCs from other sources. Furthermore, UC-MSCs are young cells that have large quantity, no ethical problems, high proliferative potential and pluripotent differentiation. UC-MSCs have been the most commonly used seed cells in clinical cell therapy. OBJECTIVE: To evaluate the efficacy and safety of UC-MSCs in the treatment of human knee OA to provide theoretical and clinical basis for stem cell therapy of OA. METHODS: The trail will be completed in Arthritis Clinic & Research Center, Beijing, China. Participants will be recruited according to established inclusion/exclusion criteria after obtaining the informed consent and the approval of the Ethics Committee (the first and second parts of the trial have been registered (https://register.clinicaltrials.gov/), with the identifier No. NCT03357770 and NCT03358654, and the third part will be carried out according to the conclusion of the first and second parts). The clinical trial will be divided into three parts: in the first part three groups will be recruited. Each group will contain three participants. The three groups of participants will be treated with high, medium and low dose of MSCs, respectively. Participants will be followed up to evaluate dose-limiting toxicity so as to determine the maximum tolerated dose. The second part will be a single-arm clinical trial. Nine participants will be recruited. The injection dose will be the maximum tolerated dose determined in the first part. Participants will be followed up to evaluate the safety and efficacy of the treatment. The third part will be a randomized controlled trial. Participants will be randomly divided into two groups (n=7 per group) and treated with MSCs and hyaluronic acid, respectively. During the trial, evaluators, participants and interveners will be unaware of grouping information and interventions. Participants will be followed up at designed time points after treatment to evaluate the safety and efficacy of the intervention. The trial will be terminated if there are unexplained local and systemic symptoms or death according to the NCI-CTCAE criteria. EXPECTED RESULTS: With reference to the previous literature, the knee pain will be relieved, the score of knee joint function will increase, and the cartilage defect area will decrease on MRI at 1-2 years after the intervention. The trail is expected to spend 3 years and 6 months. [ABSTRACT FROM AUTHOR]